Neurocrine Is Maintained at Buy by Canaccord Genuity

Neurocrine Is Maintained at Buy by Canaccord Genuity

Dow Jones03:29

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $154 to $164.

Benzinga03:19

Neurocrine Price Target Raised to $169.00/Share From $150.00 by Barclays

Neurocrine Price Target Raised to $169.00/Share From $150.00 by Barclays

Dow Jones02:10

Barclays: Maintaining the Neurocrine Biosciences (NBIX.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $150.00 to $169.00.

Barclays: Maintaining the Neurocrine Biosciences (NBIX.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $150.00 to $169.00.

Zhitong Finance02:01

Neurocrine Biosciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 18.68% Barclays $150 → $169 Maintains Overweight 05/02/2024 -3.09% BMO Capital $129 → $138 Main

Benzinga01:59

UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating

Neurocrine Biosciences (NBIX) has an average outperform rating and a price target range of $111 to $200, according to analysts polled by Capital IQ. Price: 143.01, Change: -0.02, Percent Change: -0.0

MT NewswiresMay 2 23:18